The FDA’s approval of Paradromics’ BCI clinical trial for speech restoration in paralyzed patients highlights advancements in neurotechnology. This analysis…
Regulatory Pathways
1 post
The FDA’s approval of Paradromics’ BCI clinical trial for speech restoration in paralyzed patients highlights advancements in neurotechnology. This analysis…